Edit

Iktos

http://iktos.ai/

Last activity: 09.01.2026

Active

Categories: AIBiotechDrugDiscoveryRoboticsSoftware

We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

Our de novo design algorithm is based on deep generative models with reinforcement learning. It designs novel and easy to make compounds, optimized to meet a given multi-objective blueprint, with unprecedented speed, performance, and diversity.

Please visit our webpage to know more about our products and offerings
https://iktos.ai/products/

Followers

1.1K

Mentions

Location: France

Employees: 11-50

Total raised: $16.62M

Founded date: 2016

Twitter

Investors 3

Date	Name	Website
12.03.2023	M Ventures	m-ventures...
13.03.2023	Debiopharm	debiopharm...
-	Agoranov	agoranov.c...

Funding Rounds 1

Date	Series	Amount	Investors
13.03.2023	Series A	$16.62M	-

Mentions in press and media 20

Date	Title	Description
09.01.2026	Pierre Fabre Laboratories and Iktos Announce an Integrated AI-Driven Drug Discovery Collaboration in Oncology	CASTRES, France and PARIS, Jan. 9, 2026 /PRNewswire/ -- Pierre Fabre Laboratories and Iktos, a global leader in Artificial Intelligence (AI) and Robotics on drug discovery, today announced an integrated drug discovery collaboration to ident...
08.01.2026	Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology	PARIS, FRANCE, January 8, 2026 /EINPresswire.com/ -- Iktos, a leader in Artificial Intelligence (AI) and Robotics applied to drug discovery, today announced a landmark multi-target collaboration agreement with Servier, an international inde...
08.05.2025	Iktos makes Makya drug design AI accessible on AWS Marketplace	-
08.07.2024	Iktos Corporation Iktos acquires Synsight, a life science technology company specializing in drug discovery targeting protein-protein and RNA-protein interactions.	-
08.07.2024	Iktos Corporation Iktos acquires Synsight, a life science technology company specializing in drug discovery targeting protein-protein and RNA-protein interactions.	[Ictos Co., Ltd.] Iktos acquires Synsight, a life sciences technology company specializing in drug discovery targeting protein-protein and RNA-protein interactions Ictos Co., Ltd. Press release: July 8, 2024 ** Iktos acquires Synsight, a ...
14.02.2024	Iktos Co., Ltd. France’s Iktos announces establishment of Japanese subsidiary “Iktos Co., Ltd.”	[Iktos Co., Ltd.] France’s Iktos announces establishment of Japanese subsidiary “Iktos Co., Ltd.” View in browser Ictos Co., Ltd. Press release: February 14, 2024 ** France’s Iktos announces establishment of Japanese subsidiary “Iktos C...
14.02.2024	Iktos Co., Ltd. France’s Iktos announces establishment of Japanese subsidiary “Iktos Co., Ltd.”	-
04.07.2023	Kissei introduces Iktos AI Drug Discovery System	Iktos, a company specialized in Artificial Intelligence for new drug design, announced that Kissei Pharmaceutical Co., Ltd. (“Kissei”), a Japanese pharmaceutical company with approximately 75 years of history, specialized in the field of ur...
08.06.2023	Iktos and Curreio Announce Collaboration Agreement in New Drug Discovery	Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, announced a collaboration agreement in AI for ne...
10.04.2023	Il mercato del Venture Capital a marzo 2023	Come è andato il mercato del Venture Capital a marzo 2023? Come sempre partiamo dai dati per poi passare ad alcune tra le startup, le scaleup e i round più interessanti. Il mese di marzo vede una leggera flessione della raccolta in Europa,...
10.03.2023	Iktos Raises € 15.5 Million Series a Round to Expand Its Artificial Intelligence-Based Drug Discovery Technologies and Solutions	Iktos, a company specializing in artificial intelligence for new drug discovery, announces the closing of a € 15.5 Million Series A financing co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Ca...
10.03.2023	France-based Iktos raises EUR 15.5 million in Series A	Paris, France-based company specializing in artificial intelligence for new drug discovery, Iktos, raised EUR 15.5 million in Series A funding. The Series A round took place on March 9, 2023. New investors such as M Ventures and Debiopharm ...
09.03.2023	Iktos Raises €15.5M in Series A Funding	Iktos, a Paris, France-based company specializing in artificial intelligence for new drug discovery, raised €15.5M in Series A funding. The round was led by M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. Th...
09.03.2023	Iktos raises €15.5 million Series A round for AI drug discovery service	French start-up Iktos has raised a €15.5 million Series A round fuelling its launch of its drug discovery platform. Fresh to the Iktos cap table the round is co-led by M Ventures and Debiopharm Innovation Fund, and includes Omnes Capital. I...
09.03.2023	France-based Iktos raises €15.5M to expand its AI-based drug discovery technology	Paris-based Iktos, a company that specialises in artificial intelligence for new drug discovery, announced on Thursday that it has raised €15.5M in a Series A round of funding. The round was co-led by new investors M Ventures and Debiopharm...
24.11.2022	Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 24th November 2022	This is our AI Daily Roundup today. We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and hu...
23.11.2022	Iktos Partners with Medicines for Malaria Venture in Anti-Malarial Drug Discovery	Iktos, a leader in Artificial Intelligence for new drug design, announced a collaboration with Medicines for Malaria Venture (MMV), a leading product development partnership (PDP) in the field of antimalarial drug research and development. ...
19.08.2021	Greek AI startup Intelligencia scores €10.2M in Series A round	Photo: Kwanchai Lerttanapunyaporn/Getty Images
-	Iktos	“Iktos is the only company to offer generative modeling with built-in synthetic accessibility for successful drug discovery”
-	EU-backed healthcare project rolls out platform for federated learning in drug discovery	The three-year project MELLODDY, which had received €18-million from the European Union and partnering EFPIA companies under the Innovative Medicines Initiative (IMI2), has now built a secure platform for privacy-preserving and federated le...

Iktos

Investors 3

Funding Rounds 1

Mentions in press and media 20

Reviews 0